Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran Formulation PK and Safety Study
NCT07626281Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of inclisiran in hypercholesterolemia (2 arms), sponsored by Novartis. Primary endpoints: Maximum Observed Plasma Concentration at Day 4, Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration at Day 4 and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07626281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07626281.